STAT+: Bristol Myers Squibb partners with China’s Hengrui Pharma on a dozen drugs

Bristol Myers Squibb has partnered with Hengrui Pharma on over a dozen early-stage programs, including a $600 million upfront payment and a potential value of up to $15.2 billion. The deal grants Bristol rights to four Hengrui drug candidates outside of mainland China, Hong Kong, and Macau. Hengrui will commercialize four immunology drugs from Bristol in the region.